tbuckley/cabot-search huggingface dataset:
Endothelial Glycocalyx: Not Just a Sugar Coat
Authors: Li Li, Joseph V. Bonventre
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

for the self-management of exposure and the empowerment of patients in dealing with air quality.Real-life choices to personally reduce exposure to ambient air pollution are limited, particularly in regions (such as Canada) where air quality is rather good.As shown by Ragettli and colleagues, choosing a high-versus a low-exposure route had a minor effect on exposure (9).Time spent in commute contributed 8% versus 5%, respectively, to total personal exposure to nitrogen dioxide, although traffic is its dominant local source.Given the more homogenous spatial distribution of PM 2.5 , differences between low-and high-exposure choices would likely be smaller.To echo the overstated promises of "personalized medicine" with overselling "personalized prevention" from environmental hazards is a slippery road.The large burden of diseases attributable to ambient air pollution (10, 11) will not be reduced by air quality apps, personalized tools, or empowered patients."Personalized prevention" of the air pollution burden depends on strong policy makers and governments setting science-based air quality standards and on clean air agencies who rigorously implement air management plans.The global community is very far from this goal, as only nine governments around the world adopted the PM standards proposed by the World Health Organization ( 12).Once all countries comply with these standards, the globe will be a much healthier place (13).On the basis of the findings of To and colleagues, it will also be a place with fewer cases of ACOS, although the related benefit may turn out to be smaller than expected from the threefold hazard rate.n
Re-Engineering γ δ T Cells by α β T Cell Receptor Gene Transfer Creates Potent Effector Cells with Anti-Leukemic Reactivity.
Authors: Lars T. van der Veken, Renate S. Hagedoorn, Marleen M. van Loenen, Roel Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Journal: Blood (2005)
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Authors: Adam M. Brufsky, Nancy E. Davidson
Journal: Clinical Cancer Research (2016)

The Breast Cancer Index appears to perform better than the 21-gene recurrence score in predicting 10-year disease-free survival in postmenopausal women with hormone receptor-positive lymph node-negative early-stage breast cancer. This may have implications for clinical use of first-generation versus second-generation multiparametric genomic assays. Clin Cancer Res; 22(20); 4963-5. ©2016 AACRSee related article by Sestak et al., p. 5043.
Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera
Authors: I S Tiong, D A Casolari, T Nguyen, M J M Van Velzen, K Ambler, R J D'Andrea, D M Ross
Journal: Blood Cancer Journal (2016)

Polycythaemia vera (PV) can be defined as a myeloproliferative neoplasm (MPN) with erythrocytosis and JAK2V617F (or an equivalent marker of clonality). While these simple criteria are sufficient for most cases of overt PV, an estimated 10–15% of PV patients do not have an elevated haemoglobin concentration (Hb) and may mimic JAK2-positive essential thrombocythaemia (ET). This poses a problem for accurate diagnosis and may also have clinical significance, since patients with ‘masked' PV (mPV) might receive less intense treatment leading to shortened survival compared with overt PV.1
Institutional ageism in global health policy
Authors: Peter G Lloyd-Sherlock, Shah Ebrahim, Martin McKee, Martin James Prince
Journal: BMJ (2016)

The sustainable development goals agreed in March 2016 by the United Nations General Assembly set the global development agenda for the next 15 years.They include an ambitious target to reduce premature mortality from non-communicable diseases by a third by 2030.Premature mortality, defined by the World Health Organization as deaths occurring between the ages of 15 and 70, has gained broad acceptance in health research and policy over the past decade.We argue that it is explicitly ageist, reflecting institutional ageism in global health policy.Its inclusion in the sustainable development goals sends a strong signal in favour of discriminating against older people in the allocation of health resources and the collection of data.We consider the emergence of ageist approaches in global health policy and the potential effects of ageism in the sustainable development goals.We propose a less discriminatory approach. Institutional ageismAgeism is defined as: "a process of systematic stereotyping and discrimination against people because they are old." 1 Institutional ageism differs from, but is related to, interpersonal ageism.It involves the inclusion of ageist principles in formal rules and procedures and in wider institutional cultures.It is characterised by language consistently depicting older people in negative terms. 2
Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer
Authors: Thomas Longo, Kathleen F. McGinley, Jennifer A. Freedman, Wiguins Etienne, Yuan Wu, Alexander Sibley, Kouros Owzar, Jeremy Gresham, Christopher Moy, Stephen Szabo, Joel Greshock, Hui Zhou, Yuchen Bai, Brant A. Inman
Journal: European Urology (2016)
Infusion of Pegylated Bovine Carboxyhemoglobin (PEG-COHb) Is Associated with Rapid Reversal of Progressive Acute Chest Syndrome in a Jehovah's Witness Patient with Hemoglobin SC Sickle Cell Disease
Authors: Roberta Miyeko Kato, Thomas Hofstra, Herbert J. Meiselman, Henry Jay Forman, Abe Abuchowski, Deven V. Parmar, Thomas D. Coates
Journal: Blood (2015)
Female-to-Male Transmission of HTLV-III
Authors: Stephen Schultz
Journal: JAMA (1986)

<h3>To the Editor.—</h3> In the Oct 18, 1985, issue of<i>JAMA</i>, Redfield et al<sup>1</sup>present evidence for heterosexual transmission of the human T-cell lymphotropic virus type III (HTLV-III). Male-to-female transmission has been documented previously, but female-to-male transmission has yet to be demonstrated. Approximately one tenth of 1% of all US cases of acquired immunodeficiency syndrome (AIDS) (18/14,125) have been attributed to female-to-male sexual transmission (Centers for Disease Control, national surveillance data, 1981 through October 1985). Therefore, any study supporting this mode of transmission must be rigorous. We feel that the study by Redfield et al is based on questionable data and unsound epidemiologic reasoning and that the evidence presented for female-to-male transmission is unconvincing. Our first criticism is that the means used to exclude persons with known AIDS risks were not sensitive and were subject to considerable bias. Risk factors for HTLV-III infection were ascertained through self-reporting by cases,
Error in medicine
Authors: A. Trilla
Journal: JAMA (1995)

To the Editor.  —In an excellent article published recently in JAMA , Dr Leape 1 discusses the mechanisms and some models of medical errors. In his initial statement, however, a historical error is introduced. Florence Nightingale must take credit for many important contributions to the progress of medicine and nursing, but certainly not for being the original author of the dictum, first, do no harm.  Since the time of Hippocrates (circa 500 BC), the principle of primum non nocere (the first thing [is] to do no harm or above all, do no harm) has been quoted by medical writers with respect and considered medicine's most cherished principle. 2 It has been taught this way to every medical and nursing student throughout the world and through the years. However, even the real meaning and logic of this principle has been questioned recently in an excellent review by Brewin, 3 suggesting that it
Mutations in SNORD118 cause the cerebral microangiopathy leukoencephalopathy with calcifications and cysts
Authors: Emma M Jenkinson, Mathieu P Rodero, Paul R Kasher, Carolina Uggenti, Anthony Oojageer, Laurence C Goosey, Yoann Rose, Christopher J Kershaw, Jill E Urquhart, Simon G Williams, Sanjeev S Bhaskar, James O'Sullivan, Gabriela M Baerlocher, Monika Haubitz, Geraldine Aubert, Kristin W Barañano, Angela J Barnicoat, Roberta Battini, Andrea Berger, Edward M Blair, Janice E Brunstrom-Hernandez, Johannes A Buckard, David M Cassiman, Rosaline Caumes, Duccio M Cordelli, Liesbeth M De Waele, Alexander J Fay, Patrick Ferreira, Nicholas A Fletcher, Alan E Fryer, Himanshu Goel, Cheryl A Hemingway, Marco Henneke, Imelda Hughes, Rosalind J Jefferson, Ram Kumar, Lieven Lagae, Pierre G Landrieu, Charles M Lourenço, Timothy J Malpas, Sarju G Mehta, Imke Metz, Sakkubai Naidu, Katrin Õunap, Axel Panzer, Prab Prabhakar, Gerardine Quaghebeur, Raphael Schiffmann, Elliott H Sherr, Kanaga R Sinnathuray, Calvin Soh, Helen S Stewart, John Stone, Hilde Van Esch, Christine E G Van Mol, Adeline Vanderver, Emma L Wakeling, Andrea Whitney, Graham D Pavitt, Sam Griffiths-Jones, Gillian I Rice, Patrick Revy, Marjo S van der Knaap, John H Livingston, Raymond T O'Keefe, Yanick J Crow
Journal: Nature Genetics (2016)
Opposite Effects of M1 and M2 Macrophages on Hematopoietic Stem Cell Self-Renewal and Ex Vivo Expansion
Authors: Yi Luo, Lijian Shao, Jianhui Chang, Wei Feng, Chengcheng Li, Y. Lucy Liu, Michele Cottler-Fox, Peter D Emanuel, Peter Murray, Daohong Zhou
Journal: Blood (2014)
Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study
Authors: Maryam Fouladi, Clinton. F. Stewart, Susan M. Blaney, Arzu Onar-Thomas, Paula Schaiquevich, Roger J. Packer, Amar Gajjar, Larry E. Kun, James M. Boyett, Richard J. Gilbertson
Journal: Journal of Clinical Oncology (2010)

To estimate the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetic properties of lapatinib, a selective epidermal growth factor receptor (EGFR) and ERBB2 inhibitor, in children with refractory or recurrent CNS malignancies.Lapatinib was administered orally twice daily at escalating doses starting at 300 mg/m(2) to patients who were not (stratum I) or were (stratum II) receiving steroids. Pharmacokinetic studies were performed during the first two courses. Expression of the four ERBB receptors and downstream signaling elements in tumor tissue was evaluated by immunohistochemistry.Fifty-nine patients were enrolled (stratum I, n = 32; stratum II, n = 27). Of 29 patients evaluable for toxicity in stratum I, one experienced a DLT (diarrhea) at 520 mg/m(2) twice daily, and all three receiving 1,150 mg/m(2) twice daily experienced DLTs (one each of rash, diarrhea, and fatigue). Two of 21 patients evaluable for toxicity in stratum II experienced DLTs of rash at 900 mg/m(2) twice daily. Lapatinib dosage was related linearly to area under the [concentration-time] curve from start time to 12 hours later (AUC(0-12)) and dose-normalized maximum serum concentration and AUC values for patients in stratum II were both significantly higher (P = .001) than those for patients in stratum I. Frequent, high-level expression of activated (phosphorylated) EGFR and ERBB2 receptors and downstream signal intermediates were observed in tumors, particularly in ependymomas that displayed prolonged stable disease on lapatinib therapy.Lapatinib is well tolerated in children with recurrent CNS malignancies, with rash, diarrhea, and fatigue identified as DLTs. The recommended phase II dose, regardless of steroid use, is 900 mg/m(2) twice daily.
The Disappearance of Sudden Infant Death Syndrome
Authors: Carl J. Schmidt
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Historical Trends in PM <sub>2.5</sub> -Related Premature Mortality during 1990–2010 across the Northern Hemisphere
Authors: Jiandong Wang, Jia Xing, Rohit Mathur, Jonathan E. Pleim, Shuxiao Wang, Christian Hogrefe, Chuen-Meei Gan, David C. Wong, Jiming Hao
Journal: Environmental Health Perspectives (2016)

Background:Air quality across the northern hemisphere over the past two decades has witnessed dramatic changes, with continuous improvement in developed countries in North America and Europe, but a contrasting sharp deterioration in developing regions of Asia.Objective:This study investigates the historical trend in the long-term exposure to PM2.5 and PM2.5-related premature mortality (PM2.5-mortality) and its response to changes in emission that occurred during 1990–2010 across the northern hemisphere. Implications for future trends in human exposure to air pollution in both developed and developing regions of the world are discussed.Methods:We employed the integrated exposure–response model developed by Health Effects Institute to estimate the PM2.5-mortality. The 1990–2010 annual average PM2.5 concentrations were obtained from the simulations using the WRF-CMAQ model. Emission mitigation efficiencies of sulfur dioxide (SO2), nitrogen oxides (NOx), ammonia (NH3), and primary PM are estimated from the PM2.5-mortality responses to the emission variations.Results:Estimated PM2.5-mortalities in East Asia and South Asia increased by 21% and 85% respectively, from 866,000 and 578,000 in 1990, to 1,048,000 and 1,068,000 in 2010. PM2.5-mortalities in developed regions (i.e., Europe and high-income North America) decreased substantially by 67% and 58% respectively.Conclusions:Over the past two decades, correlations between population and PM2.5 have become weaker in Europe and North America due to air pollution controls but stronger in East Asia due to deteriorating air quality. Mitigation of primary PM appears to be the most efficient way for increasing health benefits (i.e., providing the largest mortality reduction per unit emissions). However, reductions in emissions of NH3 are needed to maximize the effectiveness of NOx emission controls.Citation:Wang J, Xing J, Mathur R, Pleim JE, Wang S, Hogrefe C, Gan CM, Wong DC, Hao J. 2017. Historical trends in PM2.5-related premature mortality during 1990–2010 across the northern hemisphere. Environ Health Perspect 125:400–408; http://dx.doi.org/10.1289/EHP298
Prostacyclin and Thromboxane and the Development of Preeclampsia—Reply
Authors: James L. Mills, Richard J. Levine, Jason D. Morrow
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A randomized controlled trial of the effect of intercessory prayer on the spiritual wellbeing and quality of life of patients with cancer
Authors: I. N. Olver, H. S. Whitford
Journal: Journal of Clinical Oncology (2009)

e20708 Background: A number of scientific trials assessing the positive impact of intercessory prayer attest to centuries of anecdotal evidence, despite debate of its mechanism. However, little attention has been afforded to patients with cancer and the effect such intervention has on quality of life, including spiritual wellbeing. This study aimed to assess the effect of remote, Christian intercessory prayer on cancer patients’ quality of life, specifically their spiritual wellbeing, including their search for meaning, peace, and faith. Methods: New, consecutive patients with cancer attending an Australian cancer centre, aged 18 years or above, able to read English, and give consent were recruited. With Ethics Committee approval, this prospective, double blinded randomized controlled trial only partially divulged the nature of the study to patients who were informed of the measurements but not the inclusion of randomization to an intervention. Specifically, patients were blindly, randomly allocated to receive distant, intercessory prayer from an established Christian prayer chain (intervention) or not to receive prayer (control). All patients completed the Mental Adjustment to Cancer (MAC) scale and the Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being (FACIT-Sp) at baseline. The FACIT-Sp was re-administered six months later to assess the primary endpoint, a change in spiritual wellbeing. It was anticipated that 1000 patients were needed (allowing for 20% drop out) to achieve 80% power to detect hypothesized small differences (Cohen's d .20-.50) between groups (alpha = .05). Results: A total of 1003 eligible, consenting patients were accrued between June 2003 and May 2008. Intervention (n = 509) and control (n = 494) groups will be compared across baseline characteristics to identify any pre-existing differences. Between-within subject analyses of covariance (ANCOVAs) will be used to assess whether any differences were evident between groups across measures of spiritual wellbeing and other facets of quality of life. Conclusions: The results of these analyses will be presented. It is hoped this research will provide further empirical support for the biopsychosocialspiritual model of health. No significant financial relationships to disclose.
MicroRNA-146a suppresses IL-17–mediated skin inflammation and is genetically associated with psoriasis
Authors: Ankit Srivastava, Pernilla Nikamo, Warangkana Lohcharoenkal, Dongqing Li, Florian Meisgen, Ning Xu Landén, Mona Ståhle, Andor Pivarcsi, Enikö Sonkoly
Journal: Journal of Allergy and Clinical Immunology (2016)
Photodynamic therapy using intense pulsed light for treating actinic keratoses and photoaged skin of the dorsal hands: a randomized placebo‐controlled study
Authors: E. Kohl, C. Popp, F. Zeman, P. Unger, M. Koller, M. Landthaler, S. Karrer, R.‐M. Szeimies
Journal: British Journal of Dermatology (2016)

The efficacy of photodynamic therapy (PDT) with intense pulsed light (IPL) has been shown for treating actinic keratoses (AK) and improving photoaged skin on the face but not yet on the dorsal hands. To evaluate the efficacy of PDT with IPL for treating AK of the dorsal hands, inducing neocollagenesis and improving photoaged skin. In this prospective, randomized, placebo‐controlled, monocentric, within‐patient, observer‐blinded trial, patients with one to four mild‐to‐moderate AK on the dorsal hands were randomly allocated to two different treatment groups: methyl aminolaevulinate (MAL) and IPL (λ ≥ 600 nm, 16·2 J cm−2, three passes, Ellipse Flex PPT) (MAL‐IPL) or placebo and IPL (λ ≥ 600 nm, 16·2 J cm−2, three passes, Ellipse Flex PPT) (placebo‐IPL). Patients received three treatments at 6‐week intervals, and follow‐up was 10 weeks after the last treatment. Thirty‐seven patients aged 68·84 ± 9·28 years were randomized. The primary study end points were complete AK clearance per hand and neocollagenesis of subepidermal collagen 10 weeks after the last treatment. Ten weeks after the last treatment, complete AK clearance rates per hand were 54·5% after MAL‐IPL and 3·0% after placebo‐IPL (P < 0·0001); complete AK clearance rates per lesion were 69% and 15%, respectively (P < 0·001). The thickness of the subepidermal collagen band had increased by 290·6% (± 327·4%, P < 0·001) after MAL‐IPL and by 215·5% (± 215·3%, P < 0·001) after placebo‐IPL without any significant difference between the two groups. Ratings regarding mottled pigmentation and overall appearance by the blinded investigator were significantly higher for MAL‐IPL than for placebo‐IPL. Wrinkle size (MAL‐IPL, −23·5%, P = 0·006; placebo‐IPL, −17·7%, P = 0·010) and skin roughness (MAL‐IPL, −18·3%, P < 0·001; placebo‐IPL, −12·4%, P = 0·009) were significantly reduced in both groups without any significant difference between the two groups. On the dorsal hands, MAL‐IPL reduced AK more efficaciously than placebo‐IPL; both treatment modalities significantly improved photoaged skin.
The Phenotype High Noxa mRNA/Low NOXA Protein Levels Constitutes a Critical Achilles Heel Of Mantle Cell Lymphoma (MCL) Cells
Authors: Michael A. Dengler, Andrea Weilbacher, Matthias Gutekunst, Annette M. Staiger, Heike Horn, German Ott, Heiko van der Kuip, Walter E. Aulitzky
Journal: Blood (2013)
Successful Treatment with Intrathecal (IT) Liposomal Cytarabine (Depocyte®) in a Refractory Meningeal Relapsed Child with T-ALL.
Authors: Rosanna Parasole, Giuseppe Menna, Argia Mangione, Luciano Marchese, Francesco Menna, Mimmo Ripaldi, Vincenzo Poggi
Journal: Blood (2005)
Computerized Physician Order Entry Systems and Medication Errors
Authors: Steven M Hegedus
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal